New Vytorin study not enough of a lift

Has Vytorin been wrongly maligned? A study presented last week appeared to suggest that it had. But Forbes' Matthew Herper looks at the evidence--and talks to the experts--to find that the latest data isn't enough of a shot in the arm. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.